Singapore-based biotech firm Tychan to begin human trials for COVID-19 treatment next week

Tychan is said to begin human clinical trials next week for a potential monoclonal antibody treatment for the COVID-19 infection.

|Jun 10, 2020, 15:33:16 IST

Singapore’s Tychan, a biotechnology firm backed by state investor Temasek Holdings, said it will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19.The first phase of the trial to be conducted on 23 healthy volunteers will take about six weeks to evaluate the safety and tolerability of TY027 – a monoclonal antibody that specifically targets SARS-CoV-2, the virus that causes COVID-19.Antibodies are generated in the body to fight off infection. Monoclonal antibodies mimic natural antibodies and can be isolated and manufactured in large quantities to treat diseases in patients.Many scientists and researchers believe antibody-based therapies hold great promise for treating people already infected with the disease.[caption id="attachment_8310251" align="alignnone" width="1280"]

The structure and cross-sectional view of Human Coronavirus. It shows depicting the shape of coronavirus as well as the cross-sectional view. Image shows the major elements including the Spike S protein, HE protein, viral envelope, and helical RNA. Image credit: Wikipedia[/caption]“We will continue with the fast pace of development as we are conscious that a day saved is a day less of misery,” said Teo Ming Kian, chairman of Tychan. He added that the company reached human trials in four months, when it would usually take 12-18 months.TY027 is being explored for the treatment of patients with COVID-19 to slow the progression of the disease and accelerate recovery, as well as for its potential to provide temporary protection against infection with SARS-CoV-2.After passing key milestones in the first phase trial, Tychan will seek approval from the Singapore regulator to expand TY027 to a larger population of COVID-19 volunteer patients to establish its efficacy.Temasek Holdings is the founding investor of Tychan, which has previously developed therapeutic treatments for Zika and yellow fever.

Stroke is rising among young adults. Doctor explains why it's happening and what you must do

Stroke is increasingly affecting adults in their 30s, 40s and 50s. Experts say unhealthy lifestyles, undiagnosed high blood pressure and delayed treatment are driving the rise in younger stroke cases

3 min read

Stroke in young adults, silent symptoms and late diagnosis: India's growing brain health challenge

Neurologists warn that stroke is increasingly affecting people in their 30s and 40s, while many brain disorders progress silently before symptoms appear. They say early diagnosis, timely referrals and healthier lifestyles are key to reducing India's growing neurological disease burden.

5 min read

Brain tumours aren't always fatal, but delayed diagnosis can be: Experts explain the key warning signs

Brain tumours are frequently mistaken for common headaches, stress or age-related cognitive changes. Doctors say recognising warning signs early and adopting a brain-healthy lifestyle can improve outcomes and reduce the risk of long-term neurological complications.

2 min read

Spices, health and the Indian plate: Why chilli can be good for you—but moderation is still key

From boosting metabolism to supporting heart health, chillies offer several surprising health benefits. But experts say the amount you eat matters, and too much spice can do more harm than good.

4 min read

Organ donation: 5 myths you need to stop believing, according to a transplant specialist

Organ donation has the power to transform and save lives, but this can happen only when myths are replaced with facts. Building awareness, having open conversations and understanding the process can help families make informed decisions.